Literature DB >> 11939298

Towards eliminating lymphatic filariasis in Papua New Guinea: impact of annual single-dose mass treatment on transmission of Wuchereria bancrofti in East Sepik Province.

M J Bockarie1, E Ibam, N D Alexander, P Hyun, Z Dimber, F Bockarie, M P Alpers, J W Kazura.   

Abstract

The impact of annual single-dose community-wide treatment on the transmission of Wuchereria bancrofti was investigated in 5 villages in the East Sepik Province where pretreatment prevalence of microfilaraemia ranged from 34% to 73%. Anopheles punctulatus and An. koliensis were the only carriers of the parasite. 3 villages received diethylcarbamazine citrate (DEC) in combination with ivermectin (IVR) and 2 received DEC alone. The rate and intensity of microfilaraemia were both reduced in all 5 villages. Reduction in prevalence was between 43% and 67% in the DEC+IVR study villages and between 24% and 27% in the DEC alone villages. Density was reduced by between 81% and 95% in the DEC+IVR villages and between 69% and 74% in the DEC alone villages. Breaks in perennial transmission (failure to detect infective mosquitoes in four or more consecutive monthly collections) occurred in all 3 communities treated with DEC+IVR. Transmission was almost completely interrupted in 2 villages, where infective mosquitoes were not detected during 11 of the 12 months following treatment. We concluded that repeated annual single-dose community-wide treatment with DEC+IVR could lead to complete interruption of transmission and ultimately elimination of lymphatic filariasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11939298

Source DB:  PubMed          Journal:  P N G Med J        ISSN: 0031-1480


  6 in total

1.  Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.

Authors:  Sumadhya Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  J Trop Med       Date:  2010-12-30

2.  Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.

Authors:  Pamela J Hooper; Brian K Chu; Alexei Mikhailov; Eric A Ottesen; Mark Bradley
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

3.  Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.

Authors:  Livingstone Tavul; Moses Laman; Cade Howard; Bethuel Kotty; Anna Samuel; Catherine Bjerum; Kobie O'Brian; Steven Kumai; Matthew Amuga; Lina Lorry; Zebedee Kerry; Melvin Kualawi; Stephan Karl; Leo Makita; Lucy N John; Sibauk Bieb; James Wangi; Gary J Weil; Charles W Goss; Daniel J Tisch; William Pomat; Christopher L King; Leanne J Robinson
Journal:  PLoS Negl Trop Dis       Date:  2022-02-09

Review 4.  Neglected tropical diseases of Oceania: review of their prevalence, distribution, and opportunities for control.

Authors:  Kevin Kline; James S McCarthy; Mark Pearson; Alex Loukas; Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2013-01-31

5.  The global programme to eliminate lymphatic filariasis: health impact after 8 years.

Authors:  Eric A Ottesen; Pamela J Hooper; Mark Bradley; Gautam Biswas
Journal:  PLoS Negl Trop Dis       Date:  2008-10-08

6.  The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014).

Authors:  Hugo C Turner; Alison A Bettis; Brian K Chu; Deborah A McFarland; Pamela J Hooper; Eric A Ottesen; Mark H Bradley
Journal:  Infect Dis Poverty       Date:  2016-05-24       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.